基于网络药理学和分子对接探讨天花粉治疗肺癌的作用机制

doi:10.3760/cma.j.issn.1007-1245.2024.06.001

摘要/Abstract

摘要：

目的　基于网络药理学和分子对接的方法探讨天花粉治疗肺癌的作用靶点及机制。方法　检索时限为建库至2022年7月。采用中药系统药理学数据库和分析平台（TCMSP）、中医药综合数据库（TCMID）结合PubChem数据库相关文献筛选出天花粉的活性成分，通过TCMSP、TCMID、SwissTargetPrediction数据库获取活性成分的潜在靶点；检索GeneCards、人类孟德尔遗传综合数据库（OMIM）、TTD、DrugBank数据库收集肺癌疾病靶点；利用线上网站Venny 2.1将药物与疾病靶点取交集并绘制韦恩图；应用String数据库绘制交集靶点的蛋白互作网络；使用Cytoscape 3.8.2软件构建“药物-活性成分-疾病-靶点”网络图；运用Metascape数据库对共同靶点进行基因本体（GO）富集化分析和京都基因和基因组数据库（KEGG）通路富集分析；采用Autodock软件进行分子对接验证。结果　天花粉通过筛选得到活性成分28种，201个作用靶点；检索4大疾病数据库共获取肺癌靶点1 645个；药物与疾病共有37个交集靶点；根据连接度（degree）值大小，确定雌激素受体1（ER1）、信号转导和转录激活因子3（STAT3）、表皮生长因子受体（EGFR）为核心靶点。GO富集分析发现天花粉可能通过调节腺体发育、细胞增殖、细胞黏附、酶、受体、蛋白质的活性等治疗肺癌。KEGG通路富集分析显示天花粉可能作用于化学致癌受体激活、癌症通路、缺氧诱导因子1（HIF-1）信号通路、癌症中的微RNA、蛋白聚糖等发挥作用。分子对接结果显示，关键小分子化合物与核心靶点的结合活性显著。结论　天花粉通过多靶点、多通路机制发挥治疗肺癌的作用，为后续实验和临床应用奠定基础。

关键词:

肺癌, 天花粉, 网络药理学, 分子对接, 小分子化合物, 作用机制, 探讨

Abstract:

Objective　To investigate the target and mechanism of radix trichosanthis in the treatment of lung cancer based on network pharmacology and molecular docking. Methods　The search period was up to July 2022. The active ingredients of radix trichosanthis were selected using the TCMSP and TCMID databases combined with the PubChem database. The potential targets of active ingredients were obtained using the TCMSP, TCMID, and SwissTargetPrediction databases. The GeneCards, OMIM, TTD, and DrugBank databases were searched to collect the targets of lung cancer. The drugs were intersected with disease targets and a Venn diagram was drawn using the online web site Venny 2.1. The common target protein-protein interaction network was drawn using the String database. The "drug-active ingredient-disease-target" network diagram was constructed through Cytoscape 3.8.2 software. Gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of common targets were performed using Metascape database. Molecular docking verification was performed using Autodock software. Results　Through screening, 28 active ingredients and 201 action targets were obtained from radix trichosanthis. A total of 1 645 lung cancer targets were retrieved from the four major disease databases. There were 37 intersecting targets between the drug and disease. According to the Degree value, estrogen receptor 1 (ER1), signal transduction and transcriptional activator 3 (STAT3), and epidermal growth factor receptor (EGFR) were determined as the core targets. GO enrichment analysis found that radix trichosanthis might treat lung cancer by regulating gland development, cell proliferation, cell adhesion, receptors, enzymes, and activities of proteins. The KEGG pathway enrichment analysis revealed that radix trichosanthis might act on chemical oncogenic receptor activation, pathways in cancer, hypoxia-inducing factor 1 (HIF-1) signaling pathway, and microRNAs and proteoglycans in cancer. Molecular docking results showed that the binding activity of key small molecule compounds to the core target was significant. Conclusion　Radix trichosanthis plays a role in the treatment of lung cancer through multi-target and multi-pathway mechanisms, laying a foundation for subsequent experiments and clinical applications.

Key words:

Lung cancer, Radix trichosanthis, Network pharmacology, Molecular docking, Small molecular compound, Mechanism of action, , Investigation

崔启迪孙杉杉陆梅黄燕瑛吕文文.

基于网络药理学和分子对接探讨天花粉治疗肺癌的作用机制 [J]. 国际医药卫生导报, 2024, 30(6): 881-889.

Cui Qidi, Sun Shanshan, Lu Mei, Huang Yanying, Lyu Wenwen.

Mechanism of radix trichosanthis in the treatment of lung cancer based on network pharmacology and molecular docking [J]. International Medicine and Health Guidance News, 2024, 30(6): 881-889.

参考文献

[1] 国家药典委员会. 中华人民共和国药典[S]. 一部. 北京:中国医药科技出版社, 2020: 57.
[2] 冯果,陈娟,刘文,等. 天花粉有效成分及药理活性研究进展[J]. 微量元素与健康研究,2015,32(6):59-62.
[3] 周敬凯. 葫芦素B对胰腺癌细胞杀伤作用及相关机制研究[D].沈阳:中国医科大学,2019.
[4] 权威发布——数据"说"肺癌 [J]. 实用心脑肺血管病杂志, 2021, 29(11): 4.
[5] 李妍,韩锋锋. 肺癌中药治疗的研究进展[J]. 世界临床药物,2016,37(7):503-504,后插1-后插2. DOI:10.13683/j.wph.2016.07.016.
[6] 高善明. 运用扶正祛邪法治愈肺癌一例 [J]. 天津中医, 1992, 9(2): 20.
[7] 李英英,贾晓玮,郭立中.周仲瑛教授用复法大方辨治肺癌一例[J].成都中医药大学学报,2012,35(1):77-78.DOI:10.13593/j.cnki.51-1501/r.2012.01.012.
[8] 刘志华,孙晓波. 网络药理学:中医药现代化的新机遇[J]. 药学学报,2012,47(6):696-703. DOI:10.16438/j.0513-4870. 2012.06.001.
[9] Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines [J]. J Cheminform, 2014, 6: 13. DOI:10.1186/1758-2946-6-13.
[10] Xue R, Fang Z, Zhang M, et al. TCMID: traditional Chinese medicine integrative database for herb molecular mechanism analysis [J]. Nucleic Acids Res, 2013, 41(Database issue):D1089-D1095. DOI: 10.1093/nar/gks1100.
[11] Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution[J]. Drug Discov Today Technol, 2004, 1(4):337-341. DOI: 10.1016/j.ddtec.2004.11.007.
[12] Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings[J]. Adv Drug Deliv Rev, 2001, 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0.
[13] Kausar H, Munagala R, Bansal SS, et al. Cucurbitacin B potently suppresses non-small-cell lung cancer growth: identification of intracellular thiols as critical targets[J]. Cancer Lett, 2013, 332(1):35-45. DOI: 10.1016/j.canlet.2013.01.008.
[14] Yuan R, Zhao W, Wang QQ, et al. Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis[J]. Pharmacol Res, 2021, 170: 105748. DOI: 10.1016/j.phrs.2021.105748.
[15] 彭朝霞,曹敏,张运杰,等. HPLC测定天花粉中葫芦素B的含量[J]. 中国现代应用药学,2009,26(11):946-948.
[16] UniProt Consortium. UniProt: a worldwide hub of protein knowledge[J]. Nucleic Acids Res, 2019, 47(D1): D506-D515. DOI: 10.1093/nar/gky1049.
[17] Kim S, Chen J, Cheng T, et al. PubChem in 2021: new data content and improved web interfaces[J]. Nucleic Acids Res, 2021, 49(D1): D1388-D1395. DOI: 10.1093/nar/gkaa971.
[18] Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules[J]. Nucleic Acids Res, 2019, 47(W1): W357-W364. DOI: 10.1093/nar/gkz382.
[19] Safran M, Dalah I, Alexander J, et al. GeneCards Version 3: the human gene integrator[J]. Database (Oxford), 2010, 2010:baq020. DOI: 10.1093/database/baq020.
[20] Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018[J]. Nucleic Acids Res, 2018, 46(D1): D1074-D1082. DOI: 10.1093/nar/gkx1037.
[21] Amberger JS, Bocchini CA, Schiettecatte F, et al. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders[J]. Nucleic Acids Res, 2015, 43(Database issue): D789-D798. DOI: 10.1093/nar/gku1205.
[22] Zhou Y, Zhang Y, Lian X, et al. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents[J]. Nucleic Acids Res, 2022, 50(D1): D1398-D1407. DOI: 10.1093/nar/gkab953.
[23] Oliveros J. An interactive tool for comparing lists with Venn's diagrams (2007-2015) [DB/OL]. [2022-06-08]. https://bioinfogp.cnb.csic.es/tools/venny/index.html.
[24] Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets[J]. Nucleic Acids Res, 2021, 49(D1): D605-D612. DOI: 10.1093/nar/gkaa1074.
[25] Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets[J]. Nat Commun, 2019, 10(1): 1523. DOI: 10.1038/s41467-019-09234-6.
[26] 杨颖,刘巧,胡俊媛,等.中药天花粉对人恶性黑色素瘤细胞形态、增殖、周期和迁移的影响[J].中医药学报,2015,43(2):30-34.DOI: 10.19664/j.cnki.1002-2392.2015. 02.009.
[27] 周琳,刘菲,周光炎,路丽明.天花粉蛋白对结肠癌细胞株CMT-93凋亡及增殖的影响[J].上海交通大学学报(医学版),2014,34(3):257-262.DOI:10.3969/j.issn.1674-8115. 2014.03.001.
[28] 曹丽莉,徐妍,徐水凌,等.天花粉多糖诱导人乳腺癌MCF-7细胞凋亡及其Caspase-3和Caspase-8活化对凋亡的影响[J].浙江大学学报(医学版),2012,41(5):527-534. DOI: 10.3785/j.issn.1008-9292.2012.05.010.
[29] 张金红,徐畅,张凤川,等. 邻苯二甲酸二丁酯(DBP)诱导肿瘤细胞凋亡机制的初步研究[J]. 南开大学学报(自然科学版),2001,34(1):25-29. DOI: 10.3969/j.issn.0465-7942.2001. 01.007.
[30] 汪小莉,李华,李东,等. 葫芦素B抗肿瘤作用机制研究进展[J]. 中国药房,2021,32(17):2164-2170. DOI: 10.6039/j.issn.1001-0408.2021.17.20.
[31] Pietras RJ, Márquez DC, Chen HW, et al. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells[J]. Steroids, 2005, 70(5-7): 372-381. DOI: 10.1016/j.steroids.2005.02.017.
[32] Kawai H, Ishii A, Washiya K, et al. Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer[J]. Anticancer Res, 2005, 25(6C): 4693-4698.
[33] 刘胜岗,杨红忠,彭毅强,等. STAT3在小细胞肺癌中的表达及对血管生成的影响[J]. 肿瘤药学,2013(3):176-179. DOI: 10.3969/j.issn.2095-1264.2013.042.
[34] 周爱民. STAT3与磷酸化STAT3在非小细胞肺癌中的表达及临床意义[J]. 安徽医学,2010,31(8):871-873. DOI: 10.3969/j.issn.1000-0399.2010.08.03.
[35] 袁世洋,贺荣芝,谢军平,等. 非小细胞肺癌患者EGFR基因突变[J]. 中国老年学杂志,2019,39(18):4434-4437. DOI: 10.3969/j.issn.1005-9202.2019.18.021.
[36] 钱磊,冯继锋. PD-1信号通路在非小细胞肺癌中的研究进展[J]. 中国肿瘤外科杂志,2020,12(2):169-173. DOI: 10.3969/j.issn.1674-4136.2020.02.018.
[37] 万军,车云,康宁宁. 信号通路蛋白 Akt1、ERK1／2与 HIF-1α在肺癌组织中的表达及其临床意义[J]. 实用癌症杂志,2014(12):1515-1517,1521. DOI: 10.3969/j.issn.1001- 5930.2014.12.03.
[38] 郭树鹏,杨柳,张莉琳,等. HIF-1α信号通路在肿瘤细胞调控中的研究进展[J]. 现代生物医学进展,2015,15(16):3145-3148. DOI: 10.13241/j.cnki.pmb.2015.16.037.